ExonHit, RedPath deal

The companies terminated ExonHit's proposed acquisition of RedPath after Highmark Inc., the regional reimbursement arm for Medicare in Delaware, Washington, D.C., Maryland, New Jersey and Pennsylvania, decided to limit coverage of RedPath's PathFinder TG molecular diagnostic assay to pancreatic cancer only. The partners said they were unable to agree on revised financial terms and conditions following the decision. ...